Skip to main content

PAHC

Stock
Health Care
Drug Manufacturers - Specialty & Generic

Performance overview

PAHC Price
Price Chart

Forward-looking statistics

Beta
1.24
Risk
48.04%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Phibro Animal Health Corp operates as a diversified animal health and mineral nutrition company. It develops, manufactures, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture. The product portfolio of the company includes animal health products such as antibacterials, anticoccidials, nutritional specialty products and vaccines, and mineral nutrition products. The company operates through three segments, Animal Health, Mineral Nutrition, and Performance Products, of which key revenue is derived from the Animal Health segment which relates to the development, manufacturing, and marketing of antibacterials, nutritional specialty products, and vaccines. The entity sells its products in the U.S. and other international countries.

Company info

SectorHealth Care
IndustryDrug Manufacturers - Specialty & Generic
Employees1K
Market cap$695.0M

Fundamentals

Enterprise value$1.7B
Revenue$1.2B
Revenue per employee
Profit margin2.67%
Debt to equity289.49

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)$0.78
Dividend per share$0.48
Revenue per share$29.39
Avg trading volume (30 day)$8M
Avg trading volume (10 day)$9M
Put-call ratio

Macro factor sensitivity

Growth+0.5
Credit+5.5
Liquidity-0.4
Inflation-2.5
Commodities+0.5
Interest Rates-2.2

Valuation

Dividend yield1.59%
PEG Ratio14.89
Price to sales0.95
P/E Ratio14.89
Enterprise Value to Revenue1.45
Price to book4.27

Upcoming events

Next earnings dayMay 8, 2025
Next dividend day
Ex. dividend dayJune 4, 2025

News

Here's Why Phibro Animal Health (PAHC) is a Strong Momentum Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Investment Research (July 11, 2025)
Phibro's Feed Play Pays Off: JPMorgan Upgrades On Zoetis Deal Boost

JPMorgan upgraded Phibro Animal Health Corporation PAHC, citing strong execution following its $350 million acquisition of Zoetis' medicated feed additive and water-soluble product portfolio.

Benzinga (July 7, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free